Vir Biotechnology made headlines in 2021 for its work with GlaxoSmithKline on a treatment for COVID-19, and again in 2022 for its work with the US government on influenza.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
